Last Updated on September 8, 2026
Most marketing advice written for UK aesthetic clinics is advice to break the law. Not in a grey, arguable way. In the plain way, where a named regulation says you may not do the thing the advice tells you to do.
This guide sets out what the rule actually is, what the regulator treats as a breach, and what is left to work with. Everything below was read at source on 8 September 2026.
The rule, in one sentence
Regulation 284(1) of the Human Medicines Regulations 2012 says: a person may not publish an advertisement that is likely to lead to the use of a prescription only medicine. There are two exceptions and neither is relevant to a clinic: pathogenic agent campaigns and approved vaccination campaigns.
Botulinum toxin is a prescription only medicine. So the rule applies to it in full, and it applies to you whether or not you are the prescriber.
This is not an advertising standards preference that can be argued down. It is a statutory prohibition, and the Advertising Standards Authority enforces it through the CAP Code. The ASA issued an enforcement notice on this specific subject on 9 January 2020, stating that botulinum toxin injections are prescription only medicines and as such cannot be advertised to the public.
What CAP treats as a breach
The two rules that bite are CAP 12.12, which prohibits advertising prescription only medicines to the public, and CAP 12.18, which prohibits health professional or celebrity endorsement of them. CAP’s published advice, dated 29 October 2025, says it treats almost every reference to Botox and other botulinum toxin products as promoting a prescription only medicine and therefore a clear breach of rule 12.12.
Read that again, because the word doing the work is almost. The following are all named in CAP’s own advice:
- Social media posts or hashtags mentioning the brand name.
- Before and after photographs, because CAP reads them as efficacy claims for the medicine.
- Endorsement by a health professional or a celebrity.
- Claims that an alternative product matches the results of the medicine.
- Price lists carrying product claims that encourage selection on price.
A hashtag counts. An image caption counts. A treatment page counts. The rule is about publication to the public, not about the format.
What you may still do
Three things, and they are more than they sound.
First, you may promote a consultation. CAP’s advice is explicit that a website may promote a consultation for the treatment of lines and wrinkles as a possible outcome following that consultation, provided the medicine is not named. That is the lawful shape of the entire funnel.
Second, dermal fillers are not prescription only medicines. They may be advertised as cosmetic fillers or injected fillers, with prices, with photographs, in the ordinary way. Everything the toxin side of your business cannot do, the filler side can.
Third, botulinum toxin may be advertised directly to the medical, dental, veterinary and allied professions. Trade marketing is not consumer marketing.
The line that separates a lawful page from an unlawful one
The test is whether the publication is likely to lead to the use of the medicine. A page about lines around the eyes, what causes them, what a consultation involves, who assesses you and what the assessment covers, is a page about a clinical service. A page that names the product, shows what it did to somebody’s forehead and lists a price per area is an advertisement for a prescription only medicine wearing a clinical costume.
The practical version: write everything from the patient’s concern rather than from your stock cupboard. It is the lawful construction and it is also better marketing, because nobody wakes up wanting a prescription only medicine. They wake up unhappy about their frown.
Where the prescribing responsibility actually sits
Regulation 214 of the same regulations restricts supply of a prescription only medicine to a prescription given by an appropriate practitioner, and restricts parenteral administration to that practitioner or to a person acting under their direction. Appropriate practitioners include doctors, dentists, nurse independent prescribers and pharmacist independent prescribers.
In practice that means a non-prescriber may lawfully inject, but only under the direction of a prescriber, and General Medical Council guidance requires that prescriber to carry out a physical examination and not to prescribe remotely.
The commercial consequence is worth spelling out. The regulatory choke point in your business is the prescriber, not the injector. That is the person a careful patient would want named, and naming them is one of the few genuinely differentiating things you can publish.
What this means for the sector you are competing in
There is no statutory register of non-surgical cosmetic practitioners in England. Section 180 of the Health and Care Act 2022 gives ministers the power to create a licensing scheme. The power commenced in July 2022. No regulations have been made under it. The consultation ran in autumn 2023 and drew over 11,800 responses, the government response was published on 7 August 2025, and in February 2026 the Women and Equalities Committee reported that there is no regulation as to who can perform non-surgical cosmetic procedures.
So the market you are in is one where anyone may set up, nobody has to register, and the most searched term in the category is closed to lawful advertising. That is a difficult market. It is also a market where a clinic that publishes a named prescriber, a checkable professional registration and a plain explanation of the assessment is doing something most of its competitors are not.
A checklist you can run this afternoon
- Search your own website for the toxin brand name. Every public instance is a rule 12.12 problem, including page titles, meta descriptions, image file names and alt text.
- Search your social accounts for the same, including hashtags and captions on old posts.
- Remove before and after photographs of toxin results. Filler results may stay if you hold signed, dated evidence that they are genuine and unmanipulated.
- Check any paid search campaigns for the brand name as a keyword or in ad copy.
- Rewrite treatment pages around the concern rather than the product.
- Name your prescriber, their register and their registration number as text.
- Publish filler prices, which you lawfully may, with the date you last checked them.
Common questions
Can I mention the brand name if a patient asks in a private message?
A private, individual response to a direct question is not publication to the public in the same way a post or a page is. The prohibition is on publishing an advertisement. Broadcasting the name to a following is publication. Answering one person who has already contacted you is a conversation. If you are unsure where your own practice sits, the ASA and CAP run a free advice service.
Everyone else advertises it. Why should I not?
Because the rule does not stop applying because it is widely broken, and because the enforcement risk is not the interesting part. The interesting part is that a market where your competitors are all building on an unlawful foundation is a market where a lawful, consultation-led, prescriber-named clinic has an argument nobody else is making.
Does this apply to fillers?
No. Dermal fillers are not prescription only medicines, so regulation 284 does not apply to them. Ordinary advertising rules still do, which means claims must be substantiated, before and after photographs must be genuine and evidenced, and testimonials must be real.
What about the licensing scheme that was announced?
The August 2025 government response set out a three tier model, green, amber and red, with the highest risk procedures restricted to regulated healthcare professionals in CQC-registered providers. It also said that education standards, insurance requirements and a fees model could not be addressed at that stage. No regulations have been made. Build your marketing for the rules that exist today, and keep the prescriber and registration detail on the page, because that is what any future scheme will ask you to prove.
Everything on this page was read at source on 8 September 2026: the Human Medicines Regulations 2012 and the Health and Care Act 2022 on legislation.gov.uk, the CAP advice on botulinum toxin products and the ASA enforcement notice on asa.org.uk, the government consultation response on gov.uk, and the Women and Equalities Committee report on parliament.uk. Rules change. Check the date on this page against the date you are reading it.
The structural checks behind this research run on any website in about twenty seconds. Enter yours and read the full result on the page. Free, and we do not ask for your email.
Run the free Visibility Check